^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab-actl) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
Excerpt:
Subject eligibility will be based on PD-L1 expression as determined by a specified IHC assay.
Trial ID:
